{
    "clinical_study": {
        "@rank": "120924", 
        "arm_group": {
            "arm_group_label": "ITCA 650", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "An 39-week, open-label study to estimate the reduction in HbA1c in patients with initial\n      HbA1c >10% </=12% who are treated with ITCA 650 20 mcg/day for 13 weeks followed by ITCA 650\n      60 mcg/day for 26 weeks."
        }, 
        "brief_title": "A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men or women age 18 to 80 years with type 2 diabetes\n\n          -  On stable treatment regimen of diet and exercise alone or in combination with a\n             stable & optimal or near-optimal dose of metformin, sulfonylurea, TZD or combination\n             of these drugs\n\n          -  HbA1c >10.0% and \u226412.0%\n\n        Exclusion Criteria:\n\n          -  Prior treatment with any GLP-1 receptor agonist\n\n          -  History of hypersensitivity to exenatide or liraglutide\n\n          -  FPG >300 mg/dL\n\n          -  History of medullary thyroid cancer or a family or personal history of multiple\n             endocrine neoplasia type 2\n\n          -  Taking DPP-4 inhibitors, incretin mimetics, alpha glucosidase inhibitors,\n             meglitinides or insulin within last 3 months\n\n          -  history of pancreatitis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01785771", 
            "org_study_id": "ITCA 650-CLP-103-Sub-Study"
        }, 
        "intervention": {
            "arm_group_label": "ITCA 650", 
            "intervention_name": "ITCA 650 (exenatide in DUROS)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Exenatide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fresno", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93721"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bradenton", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34208"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33183"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Meridian", 
                        "country": "United States", 
                        "state": "Idaho", 
                        "zip": "83646"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Franklin", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46131"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valparaiso", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46383"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43213"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Franklin", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45005"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greer", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29651"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75251"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label Multi-Center Sub-Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients With Type 2 Diabetes With High Baseline HbA1c", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in HbA1c between Week 39 and Day 0", 
            "safety_issue": "No", 
            "time_frame": "39 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01785771"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Intarcia Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Intarcia Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}